Quan Anh Vu
Net worth: 257 198 $ as of 2024-06-29
Profile
Quan Anh Vu served as the Chief Executive Officer at Baleena Bioscience, Inc. in 2021.
Prior to that, he was the Managing Director at Solganick & Co., Inc. from 2019 to 2021.
From 2016 to 2019, he held the position of Vice President at Opiant Pharmaceuticals, Inc. In 2023, he will be the Chief Financial, Accounting & Business Officer at Ocugen, Inc. Additionally, from 2021 to 2023, he will serve as the Chief Operating & Business Officer at 180 Life Sciences Corp.
Mr. Vu completed his undergraduate degree at the University of California, Los Angeles.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
OCUGEN INC
0.06% | 2023-03-05 | 165,934 ( 0.06% ) | 257 198 $ | 2024-06-29 |
Former positions of Quan Anh Vu
| Companies | Position | End |
|---|---|---|
| OCUGEN, INC. | Director of Finance/CFO | 2023-08-13 |
| 180 LIFE SCIENCES CORP. | Chief Operating Officer | 2023-01-17 |
| Solganick & Co., Inc. | Corporate Officer/Principal | 2021-09-30 |
| Baleena Bioscience, Inc. | Corporate Officer/Principal | 2021-09-30 |
| OPIANT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-07-31 |
Training of Quan Anh Vu
| University of California, Los Angeles | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| OCUGEN, INC. | Health Technology |
| 180 LIFE SCIENCES CORP. | Health Technology |
| Private companies | 3 |
|---|---|
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
| Solganick & Co., Inc. | Finance |
| Baleena Bioscience, Inc. |
- Stock Market
- Insiders
- Quan Anh Vu
